lilly to acquire global license to axiron, page-38

Hardoak

is that 20% royalty on all future sales and on top-of the announced $values payable by Eli Lilly?

ie although there is reference to unknown future royalties, has the deal already crystalised most of future royalties into the announced milestone payments?

any indication of the % of the deal which will be credited to income in 2010/11 and each subsequent year? ie to maintain earnings at $45m pa will it be generated annually by this transaction or do they have to find other revenue?

This looks a very interesting stock
that product will do well with Eli Lilly
I don't see any problem re FDA, other than in the time it takes to conclude so as to start distribution/sales.

@ price 2.50
forward 2011 pe is 9 and %pa earnings 11.2

all other things being equal incl maintainence of profit level at =>$45m then
a pe of 12 would mean a price of $3.12
a pe of 15 would mean a price of $3.90

no position tonight but seriously looking at it.